A case of a potential drug interaction between clobazam and etravirine-based antiretroviral therapy

Antiviral Therapy

Volumn 17, Issue 3, 2012, Pages 589-592

  Naccarato, Mark ^a   Yoong, Deborah ^a   Kovacs, Colin ^b   Gough, Kevin ^a,c  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b MAPLE LEAF MEDICAL CLINIC   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CLOBAZAM; COTRIMOXAZOLE; EFAVIRENZ; EMTRICITABINE; ETRAVIRINE; LAMIVUDINE; LOPINAVIR; NORCLOBAZAM; RALTEGRAVIR; RITONAVIR; TENOFOVIR; VALPROIC ACID; ZIDOVUDINE;

ADULT; ANTIRETROVIRAL THERAPY; ANTIVIRAL THERAPY; ARTICLE; CASE REPORT; CD4 LYMPHOCYTE COUNT; COMPREHENSION; DAYTIME SOMNOLENCE; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSARTHRIA; GRAND MAL SEIZURE; HOSPITAL READMISSION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MOTOR PERFORMANCE; NEUROTOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; OCCIPITAL LOBE; PRIORITY JOURNAL; PROPHYLAXIS; PSYCHOMOTOR DISORDER; SEIZURE; SIDE EFFECT; SLURRED SPEECH; SPEECH DISORDER; TEMPORAL LOBE; THALAMUS; TOXOPLASMOSIS; UNSTEADINESS; VIRUS LOAD; WEAKNESS;

ADULT; ANTI-HIV AGENTS; ARYL HYDROCARBON HYDROXYLASES; BENZODIAZEPINES; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HUMANS; MALE; NEUROTOXICITY SYNDROMES; PYRIDAZINES; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 84861660081     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1953     Document Type: Article

References (18)

1. Schöller-Gyüre M, Kakuda T, Raoof A, De Smedt G, Hoetelmans R. Clinical Pharmacokinetics and pharmacodynamics of etravirine. Clin Pharmacokinet 2009; 48:561-574.
2. Scholler-Gyure M, Kakuda TN, Van Solingen-Ristea R, et al. Pharmacokinetic interaction between etravirine and fluconazole or voriconazole in HIV-negative volunteers. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy. 12-15 September 2009, San Francisco, CA, USA. Abstract A1-1299.
3. Lim ML, Min SS, Eron JJ, et al. Coadministration of lopinavir/ritonavir and phenytoin results in two-way drug interaction through cytochrome P-450 induction. J Acquir Immune Defic Syndr 2004; 36:1034-1040. (Pubitemid 38989369)
4. Ji P, Damle B, Xie J, Unger S, Grasela D, Kaul S. Pharmacokinetic interaction between efavirenz and carbamazepine after multiple-dose administration in healthy subjects. J Clin Pharmacol 2008; 48:948-956. (Pubitemid 352009496)
5. Giraud C, Tran A, Rey E, Vincent J, Treluyer JM, Pons G. In vitro characterization of clobazam metabolism by recombinant cytochrome P450 enzymes: importance of CYP2C19. Drug Metab Dispos 2004; 32:1279-1286. (Pubitemid 39410913)
6. Sennoune S, Mesdijian E, Bonneton J, Genton P, Dravet C, Roger J. Interactions between clobazam and standard antiepileptic drugs in patients with epilepsy. Ther Drug Monit 1992; 14:269-274.
7. Bentué-Ferrer D, Tribut O, Verdier MC, Debruyne D. Therapeutic drug monitoring of clobazam. Therapie 2010; 65:225-231.
8. Theis JG, Koren G, Daneman R, et al. Interactions of clobazam with conventional antiepileptics in children. J Child Neurol 1997; 12:208-213. (Pubitemid 27184797)
9. Contin M, Sangiorgi S, Riva R, Parmeggiani A, Fiorenzo A, Baruzzi A. Evidence of polymorphic CYP2C19 involvement in the human metabolism of N-desmethylclobazam. Ther Drug Monit 2002; 24:737-741. (Pubitemid 35379527)
10. Foisy MM, Yakiwchuk EM, Hughes CA. Induction effects of ritonavir: implications for drug interactions. Ann Pharmacother 2008; 42:1048-1059.
11. Ng YT, Collins SD. Clobazam. Neurotherapeutics 2007; 4:138-144. (Pubitemid 46107321)
12. Remy C. Clobazam in the treatment of epilepsy: a review of the literature. Epilepsia 1994; 35 Suppl 5:S88-S91. (Pubitemid 24274712)
13. Seo T, Nagata R, Ishitsu T, Murata T, Takaishi C, Hori M. Impact of CYP2C19 polymorphisms on the efficacy of clobazam therapy. Pharmacogenomics 2008; 9:527-537. (Pubitemid 351803914)
14. Pok PR, Mauras M, De Saint Leger MN, Kuhlmann E, Charpenel-Durat C, Navarette C. Blood concentrations of clobazam and norclobazam in a lethal case involving clobazam, meprobamate and clorazepate. Leg Med (Tokyo) 2010; 12:300-304.
15. Horn JR, Hansten P, Chan LN. Proposal for a New Tool to Evaluate Drug Interaction Cases. Ann Pharmacother 2007; 41:674-680. (Pubitemid 46625492)
16. Kiang TK, Ho PC, Anari MR, Tong V, Abbott FS, Chang TK. Contribution of CYP2C9, CYP2A6, and CYP2B6 to valproic acid metabolism in hepatic microsomes from individuals with the CYP2C9*1/*1 genotype. Toxicol Sci 2006; 94:261-271. (Pubitemid 44817142)
17. Fleming J, Chetty M. Psychotropic drug interactions with valproate. Clin Neuropharmacol 2005; 28:96-101. (Pubitemid 40471886)
18. Bowden CL, Janicak PG, Orsulak P, et al. Relation of serum valproate concentration to response in mania. Am J Psychiatry 1996; 153:765-770. (Pubitemid 26170536)